Literature DB >> 22512575

Pharmacophore development and SAR studies of imidazoline receptor ligands.

Katarina Nikolic1, Danica Agbaba.   

Abstract

Relationship between biological responses and binding affinities at I(1)/I(2)/I(3) imidazoline receptors of compounds with imidazoline, pyrroline or oxazoline moieties was studied by 2D-QSAR, 3D-QSAR and quantitative pharmacophore development approaches. Since the I(1) imidazoline receptor is involved in central inhibition of sympathicus that produce hypotensive effect, the I(2) receptor is allosteric modulator of monoamine oxidase B (MAO-B) and the I(3) receptor regulates insulin secretion from pancreatic β-cells, design and synthesis of selective I(1)/I(2)/I(3) imidazoline ligands are very important for the development of new effective therapeutic agents. New agonists and antagonists with high selectivity for I(1)/I(2)/I(3) imidazoline receptor classes have been recently synthesized and examined. The present review will highlight the main chemical diversity and pharmacophore features of selective I(1)/I(2)/I(3) imidazoline receptor ligands.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22512575     DOI: 10.2174/138955712803832636

Source DB:  PubMed          Journal:  Mini Rev Med Chem        ISSN: 1389-5575            Impact factor:   3.862


  7 in total

1.  Antagonism/Agonism modulation to build novel antihypertensives selectively triggering i1-imidazoline receptor activation.

Authors:  Fabio Del Bello; Valentina Bargelli; Carlo Cifani; Paola Gratteri; Carla Bazzicalupi; Eleonora Diamanti; Mario Giannella; Valerio Mammoli; Rosanna Matucci; Maria Vittoria Micioni Di Bonaventura; Alessandro Piergentili; Wilma Quaglia; Maria Pigini
Journal:  ACS Med Chem Lett       Date:  2015-04-03       Impact factor: 4.345

2.  Gender difference in epileptogenic effects of 2-BFI and BU224 in mice.

Authors:  Jia-Wei Min; Bi-Wen Peng; Xiaohua He; Yanan Zhang; Jun-Xu Li
Journal:  Eur J Pharmacol       Date:  2013-09-17       Impact factor: 4.432

3.  Exploring multitarget interactions to reduce opiate withdrawal syndrome and psychiatric comorbidity.

Authors:  Fabio Del Bello; Eleonora Diamanti; Mario Giannella; Valerio Mammoli; Laura Mattioli; Federica Titomanlio; Alessandro Piergentili; Wilma Quaglia; Marco Lanza; Chiara Sabatini; Gianfranco Caselli; Elena Poggesi; Maria Pigini
Journal:  ACS Med Chem Lett       Date:  2013-07-22       Impact factor: 4.345

4.  Combined Interactions with I1-, I2-Imidazoline Binding Sites and α2-Adrenoceptors To Manage Opioid Addiction.

Authors:  Maria Elena Giusepponi; Carlo Cifani; Maria Vittoria Micioni Di Bonaventura; Laura Mattioli; Alan Hudson; Eleonora Diamanti; Fabio Del Bello; Mario Giannella; Valerio Mammoli; Corinne Dalila Paoletti; Alessandro Piergentili; Maria Pigini; Wilma Quaglia
Journal:  ACS Med Chem Lett       Date:  2016-09-08       Impact factor: 4.345

5.  Behavioral effects of the imidazoline I(2) receptor ligand BU99006 in rats.

Authors:  Yanyan Qiu; David A Thorn; Yanan Zhang; Xiaohua He; Jun-Xu Li
Journal:  Behav Pharmacol       Date:  2014-04       Impact factor: 2.293

6.  The Use of the Selective Imidazoline I1 Receptor Agonist Carbophenyline as a Strategy for Neuropathic Pain Relief: Preclinical Evaluation in a Mouse Model of Oxaliplatin-Induced Neurotoxicity.

Authors:  Laura Micheli; Lorenzo Di Cesare Mannelli; Fabio Del Bello; Mario Giannella; Alessandro Piergentili; Wilma Quaglia; Donatello Carrino; Alessandra Pacini; Carla Ghelardini
Journal:  Neurotherapeutics       Date:  2020-07       Impact factor: 6.088

7.  Understanding the Biosynthesis of Paxisterol in Lichen-Derived Penicillium aurantiacobrunneum for Production of Fluorinated Derivatives.

Authors:  Yoshi Yamano; Harinantenaina L Rakotondraibe
Journal:  Molecules       Date:  2022-03-02       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.